Physician profile
James J Murray
NPI 1811077886
$10,478.41
in general payments reported to CMS, 2019-2025
41 companies · $1,900 in 2025
The $1,900 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,139 · 2020: $781 · 2021: $1,329 · 2022: $1,405 · 2023: $1,484 · 2024: $2,439 · 2025: $1,900.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,824.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,823.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,809.01 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $1,625.23 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $1,624.90 | 2021-2025 | |
| Pfizer INC. | $826.47 | 2019-2025 | |
| Lilly USA, LLC | $716.48 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Takeda Pharmaceuticals U.S.A., INC. | $530.16 | 2019-2023 | Trintellix |
| Amgen INC. | $488.72 | 2021-2025 | Evenity, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $435.92 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $359.22 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $230.44 | 2019-2024 | M-M-R II, Proquad, Vaxelis |
| Astellas Pharma US INC | $201.26 | 2019-2025 | Veozah, Myrbetriq |
| Amarin Pharma, INC. | $170.03 | 2019-2022 | |
| Exact Sciences Corporation | $157.78 | 2023-2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $141.46 | 2024-2025 | Voquezna |
| Biohaven Pharmaceutical Holding Company LTD. | $140.41 | 2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Murray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.